Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The many abilities of omalizumab and the unbeaten path.
Incorvaia C, Riario-Sforza GG, Ridolo E. Incorvaia C, et al. Among authors: riario sforza gg. J Allergy Clin Immunol. 2019 Jun;143(6):2335-2336. doi: 10.1016/j.jaci.2019.02.035. Epub 2019 Apr 20. J Allergy Clin Immunol. 2019. PMID: 31014898 No abstract available.
Omalizumab, an anti-immunoglobulin E antibody: state of the art.
Incorvaia C, Mauro M, Russello M, Formigoni C, Riario-Sforza GG, Ridolo E. Incorvaia C, et al. Drug Des Devel Ther. 2014 Feb 7;8:197-207. doi: 10.2147/DDDT.S49409. eCollection 2014. Drug Des Devel Ther. 2014. PMID: 24532966 Free PMC article.
Allergen immunotherapy in atopic dermatitis.
Ridolo E, Martignago I, Riario-Sforza GG, Incorvaia C. Ridolo E, et al. Among authors: riario sforza gg. Expert Rev Clin Immunol. 2018 Jan;14(1):61-68. doi: 10.1080/1744666X.2018.1401469. Epub 2017 Nov 10. Expert Rev Clin Immunol. 2018. PMID: 29110542 Review.
Urticaria-angioedema reaction caused by propafenone.
Incorvaia C, Pravettoni C, Riario-Sforza GG. Incorvaia C, et al. Allergy. 2006 Feb;61(2):269. doi: 10.1111/j.1398-9995.2006.00981.x. Allergy. 2006. PMID: 16409210 No abstract available.
64 results